Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Myconostica launches new fungal pneumonia tests

Myconostica : 09 September, 2008  (New Product)
Myconostica has launched a new test to assist medical and scientific professionals identify the two most common causes of fungal pneumonia.
The assay, FXG: RESP (Asp +), uses Real-Time PCR technology to accurately and rapidly identify infections caused by both Aspergillus and Pneumocystis.

Fungal pneumonia is the leading cause of infectious death in leukaemia and bone marrow transplant patients and is the most common first manifestation of AIDS.

FXG: RESP (Asp +) can identify Aspergillus and Pneumocystis within 4 hours, which account for over 95 percent of cases of fungal pneumonia.

Diagnosis followed by antifungal treatment within the first 10 days of infection reduces the mortality rate from 90 to 40 percent.

FXG: RESP (Asp +) is a sensitive and specific Assay designed to aid healthcare professionals involved in the diagnosis and treatment of fungal pneumonia. Traditional methods used to identify fungal pneumonia infections are well-documented as being inaccurate, insensitive and slow, with a result typically taking two to three days. Combining Real-Time PCR technology with Myconostica's fungal DNA extraction system, MycXtra, FXG: RESP (Asp +) provides a rapid, sensitive and specific alternative to the traditional techniques used to identify Aspergillus and Pneumocystis infection.

FXG: RESP (Asp +) is the first in a pipeline of products from Myconostica designed to assist in the diagnosis of fungal disease. Further tests in the FXG series will also target critical fungal infections, such as Candida, which cause sepsis and bloodstream infections.

Professor David Denning of the University of Manchester, chairman and chief medical officer of Myconostica said: 'Early diagnosis of invasive fungal infection significantly improves the chances of survival. This new test from Myconostica will allow healthcare professionals to rapidly identify those patients infected by Aspergillus or Pneumocystis thus enabling clinicians to prescribe appropriate drugs to treat the infection. Early identification of disease reduces the patient's exposure to inappropriate drug treatments, improves patient outcomes and reduces the hospitalisation and treatment costs associated with invasive fungal disease.'
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo